HR4623-119

Introduced

To require direct-to-consumer advertisements for prescription drugs and biological products to include truthful and not misleading pricing information.

119th Congress Introduced Jul 22, 2025

Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.

Summary

What This Bill Does

This bill, To require direct-to-consumer advertisements for prescription drugs and biological products to include truthful and not misleading pricing information., changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Government Operations, Foreign Policy.

Who Benefits and How

health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.

Who Bears the Burden and How

federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.

Key Provisions

  • Section H5908373CDBC74B549B0A88004008C3FC: 1. Short title This Act may be cited as the Plain Prescription Prices Act.
  • Section H4E53BDE63EEC4881B9A7BF95E7D20FAD: 2. Regulating advertisements for prescription drug and biological product prices Not later than one year after the date of the enactment of this Act, the...

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

This bill, To require direct-to-consumer advertisements for prescription drugs and biological products to include truthful and not misleading pricing information., changes federal law or congressional policy affecting health care providers and patients.

Key Policy Areas

Healthcare, Government Operations, Foreign Policy

Primary Purpose

This bill, To require direct-to-consumer advertisements for prescription drugs and biological products to include truthful and not misleading pricing information., changes federal law or congressional policy affecting health care providers and patients.

Policy Domains

Healthcare Government Operations Foreign Policy

Whole bill

Identified Gains
  • health care providers and patients
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih
health care providers and patients:
Identified Costs
  • federal implementing agencies
  • health care providers and patients
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih
federal implementing agencies:
health care providers and patients:

Legislative Progress

Introduced
Introduced Committee Passed
Jul 22, 2025

Ms. Williams of Georgia (for herself, Mr. Bacon, Ms. Craig, …

Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Healthcare Government Operations Foreign Policy
Actor Mappings
"the_administrator"
→ The Administrator identified in the operative section
"secretary_of_health_and_human_services"
→ Secretary of Health and Human Services

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology